科学与讲故事：运用多组分循证策略成功招募高危子宫内膜癌黑人女性参加SISTER研究

Introduction: Black women are underrepresented in national randomized clinical trials. To address known structural and interpersonal barriers to enrollment and for accurate recruitment planning, detailed enrollment statistics from screening to randomization are needed. Methods: The Social Interventions for Support in Endometrial Cancer Treatment and Recurrence (SISTER) Study is a 13-site national randomized trial that recruited Black/African American women with high-risk EC who were enrolled in the time window between diagnostic confirmation and treatment initiation. In a community-engaged process with Black EC survivors, we created a novel multi-component, evidenced-based recruitment and enrollment process to enhance recruitment and enrollment that was deployed at all SISTER Study sites. In partnership with ECANA, a Black EC cancer advocacy group, we created print and web enrollment materials focused on community-building and self-empowerment during treatment. We also developed an enrollment video that featured the PI and Black EC survivors sharing personal stories about the racial disparities in EC and the importance of the study alongside graphic depictions of randomization and intervention arms. Using an ‘early contact' and ‘waiting room' strategy, we identified participants at or prior to their first oncology visit and initiated live conversations occurring several days to weeks prior to their eligibility window. All participants considered for the study were prospectively captured and logged in the study portal allowing for accurate reporting on screening and enrollment rates. Results: From September 2021 to September 2025, 609 individuals were identified, and 540 officially screened for the trial. Of those screened, 31% (n=166) were ineligible based on clinical and non-clinical exclusion criteria. Of the remaining 374, 16% (n=59) declined being approached. Of the 315 approached for consent, 85% (n=269) consented and 13% (n=46) declined. The trial enrollment goal of 252 was met, representing 41% of all identified, 47% of those official screened, 67% of those eligible, and 80% of those approached for consent. Conclusions: When approached and invited to participate, Black women with high-risk EC chose to enroll in a randomized controlled interventional trial. Using evidenced-based community-engaged strategies, we successfully enrolled this long-standing underrepresented group requiring active treatment during a narrow eligibility window. Our enrollment rates can be used to accurately plan for appropriate representation of Black women in endometrial cancer trials, and the multi-component strategy can be used nationally to increase equitable clinical trial representation across historically excluded communities.